spark-therapeutics
Spark Therapeutics is a Philadelphia-based gene therapy company founded in 2013 with roots at Children's Hospital of Philadelphia (CHOP). Spark developed Luxturna (voretigene neparvovec-rzyl), the first FDA-approved gene therapy for a genetic disease in the United States, approved in December 2017 for the treatment of inherited retinal disease caused by biallelic RPE65 mutations. Roche acquired Spark Therapeutics in December 2019 for approximately $4.3 billion, and Spark has since been integrated into the Roche Group, operating as a Genentech subsidiary. The original sparktx.com domain now redirects to gene.com/spark. Spark does not publish any public developer APIs, OpenAPI specifications, SDKs, or GitHub organization. As a pharmaceutical/biotech operating under Roche, Spark's public technical surface is limited to patient and prescriber information for Luxturna and adverse event reporting channels (FDA MedWatch and 1-855-SPARKTX).
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles spark-therapeutics the way a machine reads it — 2 machine-readable artifacts, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — spark-therapeutics scores 12.0/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile spark-therapeutics
Each block below is one kind of artifact we hold for spark-therapeutics. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 2
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for spark-therapeutics — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Get Started 1
Portal, sign-up, and the first successful call
Design & Contract 1
Pagination, idempotency, versioning, errors, and events
Access & Security 2
Authentication, authorization, and security posture
Company 2
The organization behind the API
Other 4
Properties that don't map to a standard resource type
← All providers · Data indexed from github.com/api-evangelist/spark-therapeutics · machine-readable index on apis.io